JPH0645524B2 - External skin preparation - Google Patents
External skin preparationInfo
- Publication number
- JPH0645524B2 JPH0645524B2 JP60051656A JP5165685A JPH0645524B2 JP H0645524 B2 JPH0645524 B2 JP H0645524B2 JP 60051656 A JP60051656 A JP 60051656A JP 5165685 A JP5165685 A JP 5165685A JP H0645524 B2 JPH0645524 B2 JP H0645524B2
- Authority
- JP
- Japan
- Prior art keywords
- mucin
- skin
- gland mucin
- salivary gland
- gland
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims description 8
- 210000003079 salivary gland Anatomy 0.000 claims description 14
- 241000124008 Mammalia Species 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 3
- 108010063954 Mucins Proteins 0.000 description 20
- 102000015728 Mucins Human genes 0.000 description 20
- 230000003020 moisturizing effect Effects 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 210000003681 parotid gland Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 4
- 210000001913 submandibular gland Anatomy 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 241000283073 Equus caballus Species 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 101000972276 Homo sapiens Mucin-5B Proteins 0.000 description 3
- 102100022494 Mucin-5B Human genes 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000002633 protecting effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 229940051875 mucins Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000008273 hexosamines Chemical group 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108020001775 protein parts Proteins 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- 210000003670 sublingual gland Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
【発明の詳細な説明】 〔産業上の利用分野〕 この発明は、化粧品、医薬品、医薬部外品等の各分野に
深く関連のある皮膚外用剤に関するものである。DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to an external preparation for skin which is closely related to the fields of cosmetics, pharmaceuticals, quasi drugs and the like.
従来、皮膚外用剤の保湿剤としては、一般にグリセリ
ン、プロピレングリコール、ソルビトール、ポリエチレ
ングリコール、乳酸ナトリウム等が利用されてきたが、
近時保湿剤に関する数多くの研究がなされ、新規保湿剤
の進歩も目覚ましく、ピロリドンカルボン酸ナトリウ
ム、コラーゲン、エラスチン、デオキシリボ核酸カリウ
ム、ヒアルロン酸ナトリウム等の天然保湿因子（以下こ
れをNMF と略称する）と呼ばれるものの開発が行なわれ
ている。Conventionally, glycerin, propylene glycol, sorbitol, polyethylene glycol, sodium lactate and the like have been generally used as a moisturizing agent for external preparations for skin,
A lot of researches on moisturizers have been made recently, and the progress of new moisturizers has been remarkable, and the natural moisturizing factors (hereinafter, abbreviated as NMF) such as sodium pyrrolidonecarboxylate, collagen, elastin, potassium deoxyribonucleic acid, and sodium hyaluronate are called. What is called is being developed.
しかし、従来のグリセリン、プロピレングリコール、ソ
ルビトール、ポリエチレングリコール、乳酸ナトリウム
等の保湿性は本質的に皮膚科学上異物である物質に基づ
くものであり、一方NMF と呼ばれるものの保湿性は生体
由来の物質に基づくものであつて、皮膚科学上から好ま
しいとはいえ、使用感、保湿作用および皮膚保護作用等
がこぞつて優れているものはきわめて数少ないという問
題点がある。However, the conventional moisturizing properties of glycerin, propylene glycol, sorbitol, polyethylene glycol, sodium lactate, etc. are based on substances that are essentially foreign substances in dermatology, while the moisturizing properties of the so-called NMF are similar to those of biological origin. Although it is based, it is very preferable from the viewpoint of dermatology, but there is a problem that there are very few that are excellent in terms of feeling of use, moisturizing action and skin protecting action.
上記問題点を解決するために、この発明の皮膚外用剤に
おいてはヒトを除く哺乳動物の唾液腺ムチンを生理的有
効成分として２〜５重量％溶解した水溶液から構成する
という手段を採つたのである。In order to solve the above-mentioned problems, the external preparation for skin of the present invention takes a means of comprising an aqueous solution in which salivary gland mucin of mammals excluding human is dissolved as a physiologically active ingredient in an amount of 2 to 5% by weight.
ここで、この発明の哺乳動物とは、たとえば牛、馬、
豚、羊その他の哺乳類に属する動物であり、唾液腺ムチ
ンとは顎下腺、舌下腺または耳下腺等で合成、分泌され
る糖蛋白質（ムチン）であつて、唾液腺から抽出、精製
によつて分離される。唾液腺ムチンは糖蛋白質に分類さ
れる物質であるが、シアル酸を含む巨大分子（分子量１
０〜100万）であり、構造的には糖部分と蛋白部分とが
ο−グリコシデ結合（糖アミノ酸結合）をしていること
などから、卵アルブミン、血清の酸性糖蛋白とは区別さ
れ、一般的性質は上皮組織の分泌物である血液型物質に
類似している。唾液腺ムチンは主成分であるシアル酸
（ＳＡと略）のほかに、Ｎ−アセチルガラクトサミン
（GalNAcと略）、Ｎ−アセチルグルコサミン（GluNAcと
略）およびＤ−ガラクトース（Ｄ−Galと略）、Ｌ−フ
コース（Ｌ−Fucと略）等の糖と蛋白とからなる成分を
も含んでいて、第１表に例示したように、哺乳動物の種
類や唾液腺の種類等によつて、組成に多少の変化がある
が、糖と蛋白とは糖のヘキソサミン残基と蛋白質のセリ
ンもしくはスレオニンの水酸基とのο−グリコシド結合
により、またシアル酸は糖部分の非還元末端に位置し、
α−ケトシド結合でほかの糖に結合している。このよう
な哺乳動物 の唾液腺ムチンの具体例として、第１表に記載のもの以
外にウシ耳下腺ムチン、ブタ舌下腺ムチン、ブタ耳下腺
ムチン、ヒツジ舌下腺ムチン、ヒツジ耳下腺ムチン、ウ
マ顎下腺ムチン、ウマ舌下腺ムチン、ウマ耳下腺ムチ
ン、その他イヌ、ネコ等すべての哺乳動物の唾液腺ムチ
ンを挙げることができ、また、これらを酸、アルカリま
たはプロテアーゼのような蛋白分解酵素などによつて分
解処理したもの、さらには哺乳動物の種目、唾液腺の種
類、分解処理方法などの異なる２種以上の混合物であつ
ても支障なく使用することができる。また、この発明に
おける水溶液は唾液腺ムチンを完全に溶解したものであ
り、乳化状態を含まない。水溶液中のムチンの配合割合
は、後述する実験結果から、２〜５重量％の範囲で適当
であることが判明している。Here, the mammals of the present invention include, for example, cows, horses,
Pigs, sheep, and other mammals that belong to mammals. Salivary gland mucin is a glycoprotein (mucin) that is synthesized and secreted in the submandibular gland, sublingual gland, or parotid gland, and is extracted and purified from the salivary gland. Separated. The salivary gland mucin is a substance classified as a glycoprotein, but it is a macromolecule containing sialic acid (molecular weight 1
It is 0 to 1,000,000) and is structurally distinguished from ovalbumin and acidic glycoprotein of serum by the fact that the sugar part and the protein part have an o-glycoside bond (sugar amino acid bond). Is similar to the blood group substance, which is a secretion of epithelial tissue. In addition to sialic acid (SA), which is the main component, salivary gland mucin, N-acetylgalactosamine (GalNAc) and N-acetylglucosamine (GluNAc) and D-galactose (D-Gal), L -It also contains components such as fucose (abbreviated as L-Fuc) composed of sugars and proteins, and as shown in Table 1, the composition may vary depending on the type of mammal or the type of salivary gland. Although there are changes, sugars and proteins are ο-glycosidic bonds between the hexosamine residues of sugars and the hydroxyl groups of serine or threonine of proteins, and sialic acid is located at the non-reducing end of the sugar moiety.
It is linked to other sugars by an α-ketoside bond. Mammals like this Specific examples of salivary mucins of bovine salivary glands include bovine parotid gland mucin, porcine sublingual gland mucin, porcine parotid gland mucin, ovine sublingual gland mucin, ovine parotid gland mucin, equine submaxillary Gland mucin, equine sublingual gland mucin, equine parotid gland mucin, and other salivary gland mucins of mammals such as dogs and cats can be mentioned, and these can be used as proteolytic enzymes such as acid, alkali or protease. Therefore, it is possible to use a mixture obtained by decomposing treatment, and even a mixture of two or more species having different mammalian species, salivary gland types, decomposing treatment methods and the like without any trouble. Further, the aqueous solution in this invention completely dissolves the salivary gland mucin and does not include an emulsified state. From the experimental results described later, it has been found that the mixing ratio of mucin in the aqueous solution is suitable within the range of 2 to 5% by weight.
なお、この発明の皮膚外用剤には、化粧品、医薬部外
品、医薬品等の分野で従来広く使用されている油剤、湿
潤剤、増粘剤、各種添加剤、界面活性剤、薬効成分、香
料、防腐殺菌剤等を用途に応じて併用しても差し支えな
い。The external preparation for skin of the present invention includes oils, humectants, thickeners, various additives, surfactants, medicinal ingredients, and fragrances that have been widely used in the fields of cosmetics, quasi drugs, pharmaceuticals and the like. The antiseptic disinfectant may be used in combination depending on the application.
ヒトを除く哺乳動物の唾液腺ムチンを皮膚外用剤に生理
的有効成分として、水溶液中にその所定濃度を適用する
ことにより、唾液腺ムチンの生理的作用のうち、イオン
の調節などに基づく保湿性について特に好ましい評価が
得られる。また、唾液腺ムチンのその他の生理的作用と
して、粘性による細胞あるいは組織の保護、皮膚賦活作
用、使用感の改善作用もある。Among the physiological actions of salivary gland mucin, by applying a predetermined concentration of the salivary gland mucin of mammals excluding humans to a skin external preparation as a physiologically active ingredient, a moisturizing property based on regulation of ions, etc. A favorable evaluation is obtained. In addition, as other physiological actions of salivary gland mucin, there are also the action of protecting cells or tissues by viscous properties, the action of skin activation, and the action of improving the feeling of use.
実施例１，２および比較例１： 第２表に示す配合割合で精製ウシ顎下腺ムチンおよびそ
の他の成分を配合し、常温にて完全に溶解して化粧水と
した。なお、配合割合の％は重量％（以下同じ）であ
る。Examples 1 and 2 and Comparative Example 1: Purified bovine submandibular gland mucin and other components were blended at a blending ratio shown in Table 2, and completely dissolved at room temperature to prepare a lotion. In addition,% of the compounding ratio is weight% (the same applies hereinafter).
得られた化粧水について、成人女子２０人による官能試
験で皮膚の保湿性、保護効果、使用感の卓越性の３点を
調べ、いずれも「明らかに効果あ り」を２、「やや効果あり」を１、「効果なし」を０と
して全員の合計点を求め、さらに次式 有効性（%）＝（合計点／40）×100 から有効性（%）を計算し、得られた値を（ ）で囲
み、合計点と共に第２表に併記した。With respect to the obtained lotion, a sensory test was conducted by 20 adult women to examine three points of skin moisturizing property, protective effect, and excellence in feeling of use. “Ri” is 2, “Slightly effective” is 1, “No effect” is 0, and the total score of all is calculated, and the following formula is effective (%) = (total score / 40) × 100 Effectiveness (%) Was calculated, and the obtained value is enclosed in () and is shown in Table 2 together with the total score.
第２表の結果から精製ウシ顎下腺ムチンを用いない比較
例１の化粧水よりも、実施例１および２の化粧水がいず
れの評価項目において遥かに優れたものであり、特に保
湿性については有効性８０〜９０％という高い評価を得
た。From the results shown in Table 2, the lotions of Examples 1 and 2 are far superior in any evaluation items to the lotions of Comparative Examples 1 and 2 which do not use the purified bovine submandibular gland mucin. Received a high evaluation of 80-90% effectiveness.
以上述べたように、この発明の皮膚外用剤は、生体由来
の物質である唾液腺ムチンを、水溶液中に所定濃度で完
全に溶解したものであるから、皮膚保護効果、皮膚賦活
効果、使用感の改善などの皮膚科学上好ましい効果が発
現されることに加え、特にイオンの調節などに基づく保
湿性がきわめて優れたものとなる利点がある。As described above, the external preparation for skin of the present invention is saliva gland mucin, which is a substance derived from a living body, because it is completely dissolved at a predetermined concentration in an aqueous solution, and thus has a skin protecting effect, a skin activating effect, and a feeling of use. In addition to the expression of dermatologically favorable effects such as improvement, there is an advantage that the moisturizing property based on the regulation of ions is extremely excellent.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 印藤 八郎 大阪府大阪市東区道修町２丁目51番地 岩 瀬コスフア株式会社内 (72)発明者 今井 一仁 大阪府大阪市東区道修町２丁目51番地 岩 瀬コスフア株式会社内 (72)発明者 柴山 裕治 大阪府大阪市東区道修町２丁目51番地 岩 瀬コスフア株式会社内 (56)参考文献 特開 昭50−160413（ＪＰ，Ａ) 特開 昭59−98727（ＪＰ，Ａ) ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Inventor Hachiro Into 2-51 Doshomachi, Higashi-ku, Osaka, Osaka Prefecture Iwase Coshua Co., Ltd. (72) Kazuhito Imai 2-51 Doshomachi, Higashi-ku, Osaka, Osaka Iwase Coshua Co., Ltd. (72) Inventor Yuji Shibayama 2-51, Doshomachi, Higashi-ku, Osaka City, Osaka Prefecture Iwase Coshua Co., Ltd. (56) Reference JP-A-50-160413 (JP, A) JP-A-59 -98727 (JP, A)
Claims (1)
的有効成分として２〜５重量％溶解した水溶液からなる
皮膚外用剤。1. A skin external preparation comprising an aqueous solution containing 2 to 5% by weight of a salivary gland mucin of mammals excluding human as a physiologically active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60051656A JPH0645524B2 (en) | 1985-03-13 | 1985-03-13 | External skin preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60051656A JPH0645524B2 (en) | 1985-03-13 | 1985-03-13 | External skin preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61210013A JPS61210013A (en) | 1986-09-18 |
| JPH0645524B2 true JPH0645524B2 (en) | 1994-06-15 |
Family
ID=12892916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60051656A Expired - Fee Related JPH0645524B2 (en) | 1985-03-13 | 1985-03-13 | External skin preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0645524B2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0755896B2 (en) * | 1985-06-05 | 1995-06-14 | ポ−ラ化成工業株式会社 | Cosmetics |
| JP4424759B2 (en) * | 1997-04-28 | 2010-03-03 | あすか製薬株式会社 | Moisturizer, cosmetics and pharmaceuticals containing it |
| US6159485A (en) * | 1999-01-08 | 2000-12-12 | Yugenic Limited Partnership | N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use |
| US6808716B2 (en) | 1999-01-08 | 2004-10-26 | Ruey J. Yu | N-acetylamino acids, related N-acetyl compounds and their topical use |
| JP4642277B2 (en) * | 2001-06-21 | 2011-03-02 | 株式会社ジーシー | Saliva pretreatment tool and saliva pretreatment method |
| US7037378B2 (en) | 2003-09-24 | 2006-05-02 | Danisco Sweetners Oy | Separation of sugars |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR207237A1 (en) * | 1974-02-25 | 1976-09-22 | Thomas A | PROCEDURE FOR OBTAINING SOLUBLE LYOPHILIZED STABLE BIOLOGICAL EXTRACTS CONSTITUTED BY THERMORE RESISTANT PROTEIN COMPLEXES |
| JPS5998727A (en) * | 1982-11-26 | 1984-06-07 | Shiseido Co Ltd | Emulsified composition |
-
1985
- 1985-03-13 JP JP60051656A patent/JPH0645524B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPS61210013A (en) | 1986-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1322532C (en) | Trehalose containing cosmetic composition and method of using it | |
| KR100852367B1 (en) | Topical Skin Care Compositions | |
| US20100190742A1 (en) | Cosmetic/pharmaceutical compositions comprising hyaluronic acid and administration thereof for reducing signs of aging | |
| AU2015202010B2 (en) | Hatching fluid enzymes and uses thereof | |
| EP2145614A2 (en) | Non-irritating moisturizing or skin care composition comprising an antimicrobial agent and an emollient | |
| JPH0768114B2 (en) | Bath additive | |
| JPH0645524B2 (en) | External skin preparation | |
| JPH0692821A (en) | Cosmetic containing eucommia ulmoides leaf extract | |
| JP2003160465A (en) | Pretreatment agent for promoting transdermal absorption and make-up method using the pretreatment agent | |
| JP2008110927A (en) | Cosmetic containing royal jelly protein hydrolyzate | |
| JPH0782131A (en) | Hyaluronidase activity inhibitor and oil in water type cream base preparation | |
| JPH09188607A (en) | Trichogenous agent | |
| JPH01207220A (en) | Composition for skin | |
| US7829072B2 (en) | Serum albumin compositions for use in cleansing or dermatological products for skin or hair | |
| JPS6368512A (en) | Skin external preparations | |
| JP2018145106A (en) | Skin external compositions | |
| JPH06279294A (en) | Collagen synthesis promoter | |
| EP0213632A2 (en) | Moisture-retaining preparation for dermal use | |
| JPH06279231A (en) | Cosmetic | |
| JP2003292433A (en) | Cosmetic | |
| JPH11180832A (en) | Composition for scalp and hair | |
| JP2006028020A (en) | Cosmetic composition comprising collagen and raw sugar extract | |
| KR20210039636A (en) | Cosmetic composition for skin moisture and manufacturing method thereof | |
| JPS61172808A (en) | Skin cosmetic | |
| JPH03255014A (en) | Cosmetic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |